The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging
as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's
disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear
from a clinical standpoint.
- Subjects will be referred to the Institute for Neurodegenerative Disorders (IND) by
practicing general neurologists with genuine uncertainty regarding the subject's
- Subjects with suspected PD or PS will be evaluated clinically and with DAT imaging,
using b-CIT and SPECT. The DAT imaging procedure will take place over two days:
- On the first day participants are injected with [123I]ß CIT, an investigational
radioactive material that localizes in the brain. Study participants will also have a
thorough neurologic examination and standard neuropsychological testing, including
testing of memory, concentration, abstraction and visual spatial functions.
- Twenty-four hours later study participants return to the Institute for
Neurodegenerative Disorders where an investigational scanning procedure will be used to
obtain SPECT (single photon emission computed tomography) images of the brain.
- Subjects will be asked to return within 3 months following the imaging study to have a
repeat neurological examination by the two study neurologists at IND.
- Subjects will be asked to return at about 6 months and possibly again at one year
following the imaging study for a final clinical evaluation by one of the study
neurologists at IND.
- Age >21
- Any parkinsonian or extrapyramidal symptoms
- Parkinsonian symptoms for < 2 years duration.
- No significant abnormalities on screening laboratory studies including: CBC, Chem-20
- Willingness to comply with study protocol.
- Significant medical disease including abnormalities on screening biochemical or
hematological labs or abnormal electrocardiogram (ECG).